Findings on Azithromycin as a COVID-19 Intervention in a New York City Study
In a study of hospitalized COVID-19 patients in New York City, the use of azithromycin alone did not significantly alter the hazard ratio for in-hospital mortality. Additionally, patients receiving azithromycin did not exhibit higher odds of cardiac arrest or abnormal ECG findings compared to those receiving hydroxychloroquine, a combination of both drugs, or neither drug.
0
1
Contributors are:
Who are from:
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Learn After
Hazard ratio for time to in-hospital mortality amongst hospitalized COVID-19 patients in New York City were not significantly different for those given Azithromycin, Hydroxychloroquine, or a combination
Proportion of abnormal ECG findings in hospitalized COVID-19 patients in New York City were higher amongst those who received Azithromycin+Hydroxychloroquine and Hydroxychloroquine
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State